Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Conmed (CNMD) EBIT Margin (2016 - 2026)

Conmed filings provide 17 years of EBIT Margin readings, the most recent being 8.02% for Q1 2026.

  • On a quarterly basis, EBIT Margin rose 305.0% to 8.02% in Q1 2026 year-over-year; TTM through Mar 2026 was 8.18%, a 560.0% decrease, with the full-year FY2025 number at 7.46%, down 786.0% from a year prior.
  • EBIT Margin hit 8.02% in Q1 2026 for Conmed, down from 9.81% in the prior quarter.
  • In the past five years, EBIT Margin ranged from a high of 20.75% in Q3 2024 to a low of 0.44% in Q4 2022.
  • Median EBIT Margin over the past 5 years was 9.26% (2022), compared with a mean of 9.62%.
  • Biggest five-year swings in EBIT Margin: skyrocketed 1578bps in 2023 and later crashed -1723bps in 2025.
  • Conmed's EBIT Margin stood at 0.44% in 2022, then soared by 3616bps to 15.35% in 2023, then fell by -1bps to 15.18% in 2024, then tumbled by -35bps to 9.81% in 2025, then fell by -18bps to 8.02% in 2026.
  • The last three reported values for EBIT Margin were 8.02% (Q1 2026), 9.81% (Q4 2025), and 3.52% (Q3 2025) per Business Quant data.